
ABK Biomedical Commences Pivotal Study in Hepatocelluar Cancer with First Patient Treated Using Microsphere Technology
ABK Biomedical, a company focused on embolic microspheres for cancer treatment, announced the treatment of the first patient in its Route90 US IDE Pivotal study. The medical procedure involved Eye90 microspheres radioembolization and was conducted by Dr. Eric A. Wang, an esteemed figure in the field of interventional radiology, with Charlotte Radiology in Charlotte, North Carolina.
The company received FDA approval for the study in May of this year. The study is expected to enroll approximately 120 individuals with data expected in 2025 according to clinicaltrials.gov.
The pivotal study aims to validate the effectiveness and safety of this Y90 radioembolization technology for the treatment of hepatocellular cancer. Approximately 41,000 new cases of liver cancer are diagnosed every year in the United States with about 30,000 deaths. Five year survival is only 21%.
Dr. Wang expressed his enthusiasm, emphasizing the potential for groundbreaking advancements in liver cancer treatment, particularly for patients grappling with Hepatocellular Cancer (HCC). Over the past four decades, the incidence of liver cancer has tripled, while mortality rates have more than doubled, painting a grim picture of the challenges it poses.